Form 4: Anixa Biosciences Officer Acquires 350,000 Stock Options

Michael Catelani, President, COO & CFO of Anixa Biosciences, Inc., reports the acquisition of 350,000 employee stock options.

Summary

• On January 2, 2025, Michael Catelani, President, COO & CFO of Anixa Biosciences, Inc., acquired 350,000 employee stock options.
• The options, granted under the 2018 Share Incentive Plan, have an exercise price of $2.37.
• The options vest in 36 equal monthly installments starting January 31, 2025, and expire on January 2, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reports a standard executive compensation practice. The grant of options is neither overwhelmingly positive nor negative on its own.

Positives

• The grant of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The size of the grant and vesting schedule are typical for executives at similar stage companies.

Stakeholder Impact

• The stock option grant could incentivize the executive to improve company performance, benefiting shareholders.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates